Heterocyclic compounds and uses as anticancer agents
US11612602B2 · kind B2 · utility
0Cited by
19References
20Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 24, 2020 |
| Grant date | Mar 28, 2023 |
| Priority date | — |
| Expiry date | Dec 23, 2040 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D487/04
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure provides pharmaceutical compounds, compositions and methods, especially as they are related to compositions and methods for the treatment of tumors and related diseases related to the dysregulation of kinase (such as EGFR (including HER), Alk, PDGFR, but not limited to) pathways.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.